Discounted Cash Flow
Tandem Diabetes Care Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $84.2m | $-83.4m | $-70.1m | -99.0% | — |
| 2017 | $107.6m (27.7%) | $-73.0m (12.5%) | $-71.9m (-2.5%) | -67.9% (31.5%) | — |
| 2018 | $183.9m (70.9%) | $-122.6m (-67.9%) | $-11.3m (84.3%) | -66.7% (1.8%) | — |
| 2019 | $362.3m (97.0%) | $-24.8m (79.8%) | $22.4m (297.8%) | -6.8% (89.8%) | — |
| 2020 | $498.8m (37.7%) | $-34.4m (-38.9%) | $-2.7m (-112.2%) | -6.9% (-0.9%) | — |
| 2021 | $702.8m (40.9%) | $15.6m (145.3%) | $97.2m (3648.0%) | 2.2% (132.1%) | $0.25 |
| 2022 | $801.2m (14.0%) | $-94.6m (-707.7%) | $16.4m (-83.2%) | -11.8% (-633.0%) | $-1.47 (-688.0%) |
| 2023 | $747.7m (-6.7%) | $-222.6m (-135.3%) | $-58.6m (-458.1%) | -29.8% (-152.2%) | $-3.43 (-133.3%) |
| 2024 | $940.2m (25.7%) | $-96.0m (56.9%) | $5.0m (108.5%) | -10.2% (65.7%) | $-1.47 (57.1%) |
| 2025 | $1.0b (7.9%) | $-204.7m (-113.2%) | $-29.7m (-694.1%) | -20.2% (-97.5%) | $-3.04 (-106.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.